Skip to main content
. 2021 May 3;25(11):4922–4937. doi: 10.1111/jcmm.16280

FIGURE 6.

FIGURE 6

NFAT5 enhances fibrosis of MCs by activating AKT. A, The mRNA levels of NFAT5 in MCs after treatment with sh‐NFAT5 determined by RT‐qPCR. B, The protein expression of NFAT5, p‐AKT and AKT in MCs after treatment with sh‐NFAT5 under HG condition measured by Western blot assay. C, The protein expression of p‐GSK3β and GSK3β in MCs after treatment with sh‐NFAT5 under HG condition measured by Western blot assay. D, The mRNA levels of NFAT5 in MCs after treatment with oe‐NFAT5 + AKT inhibitor under HG condition determined by RT‐qPCR. E, The protein expression of NFAT5, p‐AKT and AKT in MCs after treatment with oe‐NFAT5 + AKT inhibitor under HG condition measured by Western blot assay. F, The protein expression of collagen IV, fibronectin and TGF‐β1 in MCs after treatment with oe‐NFAT5 + AKT inhibitor under HG condition measured by Western blot assay. *P < .05 compared with MCs treated with NG, sh‐NC or oe‐NC. #P < .05 compared with MCs treated with oe‐NFAT5 (The data results are measurement data expressed by mean ± standard deviation. One‐way analysis of variance was used for comparison among multiple groups followed by Tukey's post hoc test, and the experiment was repeated 3 times)